Ionis recognizes the importance of Independent Medical Education (IME) and is committed to supporting programs that enhance patient care. Ionis supports targeted high-quality accredited and non-accredited medical education programs to advance excellence in healthcare by improving disease awareness, clinical knowledge, and multidisciplinary management within our therapeutic areas of focus.
IME is defined as education that is evidence-based, fair-balanced, unbiased, and independent of industry influence. Therefore, all aspects related to IME including but not limited to the agenda, content, and faculty, must remain fully independent and be under the sole control of the activity organizers. Ionis will not provide any guidance to the IME provider. All accredited programs must follow the standards set forth in the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education.
Funding Priorities:
Requests with multiple potential supporters are preferred. Due to the number of requests received not all submitted requests will be approved or approved at the amount requested. Ionis will consider funding requests in the following therapeutic areas of focus for medical educational programs in the United States:
Therapeutic Areas of Focus
Hereditary Angioedema:
- Current treatment challenges, unmet needs of patients, and investigational drugs in late-stage development for this rare disease.
Severe Hypertriglyceridemia including genetic conditions such as Familial Chylomicronemia Syndrome:
- Pathophysiology, disease burden, and management of elevated triglycerides.
- Current treatment challenges, unmet needs of patient, and investigational drugs in late-stage development.
Grant Submission Process:
All IME grant request applications must be submitted through our online Ionis Medical Grants portal by clicking here: Apply Now. Please note that the Grant requests must be submitted at least 60 calendar days prior to the program/event start date.
The following elements will be required when submitting the online grant request application. The submitter will be able to save their work and continue at another time. In addition to the required fields on our application form, the submitter will have the opportunity to upload PDF documents of additional information which may be relevant or taken into consideration.
- Requesting Organization
- Program Title
- Program Description
- Needs Assessment
- Needs Assessment References
- Program Learning Objectives
- Information if program has been held previously
- Designation if program is affiliated with a congress
- Partner Organization Information
- Funding decision needed by date
- Program Start Date
- Program End Date
- Total Number of Activities Planned
- Activity Type (Live in Person, Live Virtual, Hybrid, Enduring)
- Activity Location
- Number of Speakers/Faculty Members
- Geographic Reach
- Activity Target Audience
- Expected Number of Attendees
- Expected Audience Information
- Audience Generation Tactics
- Activity Start/End Dates
- Accrediting Bodies and Number of Credit Hours
- Outcome Measures
- Detailed Budget
- Amount Requested from Ionis
Please note that the recipient of the grant must be an appropriate organization such as a hospital, university, school of medicine, nursing, or pharmacy, a professional society or association, a medical education communication company, or other institution specializing in specific healthcare-related disciplines (e.g., public health, quality improvement). Ionis does not support IME grant requests from healthcare providers, including individual physicians, private practice groups, group purchasing organizations, managed care organizations, preferred provider organizations, or similar institutions.
Contact Information
If you have any questions regarding the Ionis IME Grant program, please email [email protected].
For Technical Support with the Ionis Grant Portal, please contact SteepRock Client Services via email at [email protected] or phone at +1 (718) 576-1406 (M-F 8am – 6pm US ET).
Global and United States IME grants requests for amyloid transthyretin cardiomyopathy (ATTR-CM) and amyloid transthyretin polyneuropathy (ATTR-PM) will now be submitted to and reviewed by our global development and commercialization partner AstraZeneca. Please visit www.astrazenecagrants.com to review the application procedure and/or to submit.
